Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer

A Single Institutional Experience of 56 Patients

Ji Woong Kwon, Joon Ho Yoon, Myong Cheol Lim, Jungnam Joo, Heon Yoo, Sang Hoon Shin, Sang Yoon Park, Sang Hyeon Lee, Yeon Joo Kim, Joo Young Kim, Ho Shin Gwak

Research output: Contribution to journalArticleResearchpeer-review

Abstract

CONCLUSIONS: Surgical resection for single or symptomatic brain metastases from ovarian cancer prolonged OS significantly. Multimodality treatment, including control of systemic cancer, appeared to be an important factor in prolonging OS.

OBJECTIVES: The most appropriate treatments for brain metastases from ovarian cancer have not been established mainly because of its rarity. The objective of this study was to describe clinical results of treatment and prognostic factors of patients with brain metastases from ovarian cancer treated at a single institution.

MATERIALS AND METHODS: We retrieved information from the electronic medical records of 56 consecutive patients (2.8%) with brain metastases, from a total of 2008 patients with ovarian cancer. Endpoints were the pattern of treatment failure, progression-free survival, and overall survival (OS).

RESULTS: Radiation was the most common initial treatment for brain metastases (59%), followed by surgery (23%). The median progression-free survival was 9.8 months. Radiological progression was confirmed in 20 patients: 7 had leptomeningeal carcinomatosis (37%), 8 had local recurrence, and 5 had distant recurrence. Median OS was 11.25 months, and the 1-year OS rate was 48.2%. Patients received surgery for single metastasis as initial treatment showed median OS of 24.1 months, which was significantly prolonged compared with the other patients (P = 0.0002). Of the 48 patients who died, 29 (60%) died of systemic disease and 7 (15%) died of central nervous system progression. Karnofsky Performance Status greater than or equal to 70, control of systemic cancer, serous histology, and surgery for brain metastases were associated with improved OS in multivariable analysis (P < 0.05).

Original languageEnglish
Pages (from-to)1631-1638
Number of pages8
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume28
Issue number8
DOIs
StatePublished - 1 Oct 2018

Fingerprint

Ovarian Neoplasms
Neoplasm Metastasis
Brain
Survival
Therapeutics
Disease-Free Survival
Meningeal Carcinomatosis
Karnofsky Performance Status
Recurrence
Electronic Health Records
Treatment Failure
Neoplasms
Histology
Survival Rate
Central Nervous System
Radiation

Cite this

Kwon, Ji Woong ; Yoon, Joon Ho ; Lim, Myong Cheol ; Joo, Jungnam ; Yoo, Heon ; Shin, Sang Hoon ; Park, Sang Yoon ; Lee, Sang Hyeon ; Kim, Yeon Joo ; Kim, Joo Young ; Gwak, Ho Shin. / Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer : A Single Institutional Experience of 56 Patients. In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 ; Vol. 28, No. 8. pp. 1631-1638.
@article{7bdbee3091c049d8b83bed65e8c7b88b,
title = "Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: A Single Institutional Experience of 56 Patients",
abstract = "CONCLUSIONS: Surgical resection for single or symptomatic brain metastases from ovarian cancer prolonged OS significantly. Multimodality treatment, including control of systemic cancer, appeared to be an important factor in prolonging OS.OBJECTIVES: The most appropriate treatments for brain metastases from ovarian cancer have not been established mainly because of its rarity. The objective of this study was to describe clinical results of treatment and prognostic factors of patients with brain metastases from ovarian cancer treated at a single institution.MATERIALS AND METHODS: We retrieved information from the electronic medical records of 56 consecutive patients (2.8{\%}) with brain metastases, from a total of 2008 patients with ovarian cancer. Endpoints were the pattern of treatment failure, progression-free survival, and overall survival (OS).RESULTS: Radiation was the most common initial treatment for brain metastases (59{\%}), followed by surgery (23{\%}). The median progression-free survival was 9.8 months. Radiological progression was confirmed in 20 patients: 7 had leptomeningeal carcinomatosis (37{\%}), 8 had local recurrence, and 5 had distant recurrence. Median OS was 11.25 months, and the 1-year OS rate was 48.2{\%}. Patients received surgery for single metastasis as initial treatment showed median OS of 24.1 months, which was significantly prolonged compared with the other patients (P = 0.0002). Of the 48 patients who died, 29 (60{\%}) died of systemic disease and 7 (15{\%}) died of central nervous system progression. Karnofsky Performance Status greater than or equal to 70, control of systemic cancer, serous histology, and surgery for brain metastases were associated with improved OS in multivariable analysis (P < 0.05).",
author = "Kwon, {Ji Woong} and Yoon, {Joon Ho} and Lim, {Myong Cheol} and Jungnam Joo and Heon Yoo and Shin, {Sang Hoon} and Park, {Sang Yoon} and Lee, {Sang Hyeon} and Kim, {Yeon Joo} and Kim, {Joo Young} and Gwak, {Ho Shin}",
year = "2018",
month = "10",
day = "1",
doi = "10.1097/IGC.0000000000001341",
language = "English",
volume = "28",
pages = "1631--1638",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Wolters Kluwer Health",
number = "8",

}

Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer : A Single Institutional Experience of 56 Patients. / Kwon, Ji Woong; Yoon, Joon Ho; Lim, Myong Cheol; Joo, Jungnam; Yoo, Heon; Shin, Sang Hoon; Park, Sang Yoon; Lee, Sang Hyeon; Kim, Yeon Joo; Kim, Joo Young; Gwak, Ho Shin.

In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 28, No. 8, 01.10.2018, p. 1631-1638.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer

T2 - A Single Institutional Experience of 56 Patients

AU - Kwon, Ji Woong

AU - Yoon, Joon Ho

AU - Lim, Myong Cheol

AU - Joo, Jungnam

AU - Yoo, Heon

AU - Shin, Sang Hoon

AU - Park, Sang Yoon

AU - Lee, Sang Hyeon

AU - Kim, Yeon Joo

AU - Kim, Joo Young

AU - Gwak, Ho Shin

PY - 2018/10/1

Y1 - 2018/10/1

N2 - CONCLUSIONS: Surgical resection for single or symptomatic brain metastases from ovarian cancer prolonged OS significantly. Multimodality treatment, including control of systemic cancer, appeared to be an important factor in prolonging OS.OBJECTIVES: The most appropriate treatments for brain metastases from ovarian cancer have not been established mainly because of its rarity. The objective of this study was to describe clinical results of treatment and prognostic factors of patients with brain metastases from ovarian cancer treated at a single institution.MATERIALS AND METHODS: We retrieved information from the electronic medical records of 56 consecutive patients (2.8%) with brain metastases, from a total of 2008 patients with ovarian cancer. Endpoints were the pattern of treatment failure, progression-free survival, and overall survival (OS).RESULTS: Radiation was the most common initial treatment for brain metastases (59%), followed by surgery (23%). The median progression-free survival was 9.8 months. Radiological progression was confirmed in 20 patients: 7 had leptomeningeal carcinomatosis (37%), 8 had local recurrence, and 5 had distant recurrence. Median OS was 11.25 months, and the 1-year OS rate was 48.2%. Patients received surgery for single metastasis as initial treatment showed median OS of 24.1 months, which was significantly prolonged compared with the other patients (P = 0.0002). Of the 48 patients who died, 29 (60%) died of systemic disease and 7 (15%) died of central nervous system progression. Karnofsky Performance Status greater than or equal to 70, control of systemic cancer, serous histology, and surgery for brain metastases were associated with improved OS in multivariable analysis (P < 0.05).

AB - CONCLUSIONS: Surgical resection for single or symptomatic brain metastases from ovarian cancer prolonged OS significantly. Multimodality treatment, including control of systemic cancer, appeared to be an important factor in prolonging OS.OBJECTIVES: The most appropriate treatments for brain metastases from ovarian cancer have not been established mainly because of its rarity. The objective of this study was to describe clinical results of treatment and prognostic factors of patients with brain metastases from ovarian cancer treated at a single institution.MATERIALS AND METHODS: We retrieved information from the electronic medical records of 56 consecutive patients (2.8%) with brain metastases, from a total of 2008 patients with ovarian cancer. Endpoints were the pattern of treatment failure, progression-free survival, and overall survival (OS).RESULTS: Radiation was the most common initial treatment for brain metastases (59%), followed by surgery (23%). The median progression-free survival was 9.8 months. Radiological progression was confirmed in 20 patients: 7 had leptomeningeal carcinomatosis (37%), 8 had local recurrence, and 5 had distant recurrence. Median OS was 11.25 months, and the 1-year OS rate was 48.2%. Patients received surgery for single metastasis as initial treatment showed median OS of 24.1 months, which was significantly prolonged compared with the other patients (P = 0.0002). Of the 48 patients who died, 29 (60%) died of systemic disease and 7 (15%) died of central nervous system progression. Karnofsky Performance Status greater than or equal to 70, control of systemic cancer, serous histology, and surgery for brain metastases were associated with improved OS in multivariable analysis (P < 0.05).

UR - http://www.scopus.com/inward/record.url?scp=85055645050&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001341

DO - 10.1097/IGC.0000000000001341

M3 - Article

VL - 28

SP - 1631

EP - 1638

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -